NovoCure (NVCR) Q2 2026: Patient Growth and Guidance Lift Drive Big Beat
As seen on the 24/7 Wall St. homepage on July 23, 2026.
NovoCure crushed expectations with active patients surging 18% to 5,128 and swinging to positive Adjusted EBITDA, sending the cancer therapy company to a $0.13 loss per share that beat estimates by 61%. The company lifted full-year revenue guidance to $710 million to $725 million on the strength of Optune Lua and Optune Pax, which together pulled in $7 million this quarter.
Continue ReadingShow less
NovoCure posted a loss of $0.13 per share for Q2 2026, coming in 61% better than the consensus estimate of roughly $0.33. Revenue landed at $183.6 million, about 6% above the $172.7 million analysts had expected. The company also swung to positive Adjusted EBITDA during the quarter, a meaningful step forward for a business that has been running at a loss while scaling its commercial infrastructure.
A key driver of the outperformance was patient growth: active patients rose 18% to 5,128, reflecting continued adoption of NovoCure's Tumor Treating Fields technology. The newer devices, Optune Lua and Optune Pax, contributed $7 million in combined revenue this quarter, underscoring the early commercial traction of the company's pipeline beyond its established glioblastoma indication.
Sponsored
Twelve Tabs, One Thesis
Your Research Resets Every Morning
The quote page in one tab. Filings in another. A chart you rebuilt from scratch, a transcript you never went back and found, a screener whose settings you will redo next week. Nothing you built yesterday is still there.
AlphaSpace replaces all of it with one screen you arrange yourself. Earnings calendar, estimate versus actual, the call transcript, live news, your own charts, every panel wired to whatever ticker you click. Close the browser and it is all still sitting there tomorrow.
See What a Built View Looks Like →
(Sponsor)
With momentum building, NovoCure raised its full-year revenue guidance to a range of $710 million to $725 million. Looking back over recent quarters, the Q2 2026 result is a sharp contrast to Q1 2026, when the company missed estimates with a loss of $0.62 per share, making the degree of sequential improvement all the more notable for investors watching the turnaround trajectory.
Mentioned: NVCR